PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET

Company Participants

Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy

Stuart Peltz - Chief Executive Officer

Matthew Klein - Chief Operating Officer

Eric Pauwels - Chief Business Officer

Emily Hill - Chief Financial Officer

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald

Eric Joseph - JPMorgan

Joseph Thome - Cowen

Alexander Xenakis - Truist

Raju Prasad - William Blair

Gena Wang - Barclays

Danielle Brill - Raymond James

Kelly Shi - Jefferies

Judah Frommer - Credit Suisse

Tazeen Ahmad - Bank of America

Operator

Hello. Thank you for standing by. And welcome to the PTC Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions]. Please be advised that today's conference maybe recorded.

I would now like to hand the conference over to your speaker today, Kylie O'Keefe.

Kylie O'Keefe

Good afternoon, and thank you for joining us today to discuss the PTC Therapeutics third quarter 2022 corporate update and financial results. I'm joined today by our Chief Executive Officer, Stuart Peltz; our Chief Operating Officer, Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Emily Hill. Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our Investor Relations Web site in conjunction with the call, which contains our forward-looking statements. Our actual results could materially differ from these forward-looking statements, as such statements are subject to risks that can materially and adversely affect our business and results of operation. For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as the company's other SEC filings. We will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and a reconciliation of GAAP to non-GAAP is available in today's earnings release.

With that, let me pass the call over to our CEO, Stuart Peltz. Stu?

Stuart Peltz

Thanks, Kylie. Good afternoon, everyone and thank you for joining the call. I'm pleased to share PTC’s strong third quarter results. We continue to demonstrate strong execution and are moving forward on our 2022 milestones. Ore marketed products continue to generate strong revenue growth and we are advancing our broad and deep pipeline of new therapy to treat diseases with significant unmet medical needs. Our mission at PTC is to discover, develop and commercialize innovative therapies and to bring them to patients with rare disorders, and in doing so, to create significant value for all of our stakeholders. Today, PTC has five marketed products and seven development programs focused on treating diseases of high unmet medical need. We continue to build a robust pipeline of potential new therapies that at steady state we expect to deliver one therapy every two to three years.